Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets

A Dutch patent court found Merck infringed Halozyme's EP 2,797,622 patent and ordered MSD BV to halt manufacturing, marketing, use and related activities for Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands; the court also rejected Merck's patent-invalidity arguments. The injunction blocks the subcutaneous product in those markets, while patients retain access to intravenous Keytruda, which is not covered by the patent or order. The ruling follows a German preliminary injunction issued in December 2025; separate U.S. litigation over QLEX remains ongoing, and Halozyme says the MDASE dispute will not affect its ENHANZE licensing program.

Analysis

The market-relevant change is bargaining leverage over Merck’s subcutaneous lifecycle strategy, not an immediate loss of Keytruda demand: IV remains an alternative, so the near-term economic impact depends on how much convenience-driven uptake Merck expected and how quickly patients/providers substitute. Europe-specific disruption should not be translated into a global revenue hit; the U.S. case remains separate and unresolved.

For HALO, the decision can raise the option value of its MDASE portfolio if it survives appeal and supports a license or settlement, but the release provides no damages, royalty terms, affected-sales estimate, or evidence of a near-term cash-flow contribution. The company’s explicit separation of MDASE from ENHANZE argues against marking down existing ENHANZE partner economics on this news alone. For MRK, the bigger second-order risk is delayed or less differentiated SC conversion—not an established impairment to the underlying franchise. Competitors’ SC programs are not automatically exposed: patent scope, formulation and jurisdiction matter.

Over days, headline-driven HALO strength and MRK weakness may overshoot the direct European exposure. Over 1–3 months, watch appeals, any stay or settlement, and MRK commentary on launch plans; the U.S. litigation could extend the strategic overhang. Over 6–18 months, the key question is whether the ruling produces licensing leverage or merely years of costly, jurisdiction-specific enforcement. Contrarian point: the injunction sounds broad geographically, but continued IV access and uncertain finality cap the immediate commercial read-through.

Key Decisions for Investors

• Do not chase HALO solely on the injunction headline. Treat a small, event-driven HALO-over-MRK pair as a watch/conditional trade only after checking current prices and the market-implied move; reduce or exit if the Dutch order is stayed, overturned, or narrowed on appeal.
• For MRK, avoid treating this as a Keytruda franchise impairment. Reassess only if Merck quantifies material SC-launch delays or changes lifecycle guidance; continued IV use and substitution rates are key offsets to verify.
• Track the Dutch appeal and any stay, the German injunction’s status, and the U.S. case docket over the next 1–3 months. A reversal or stay weakens HALO’s leverage thesis; a durable ruling plus settlement/license economics would strengthen it.
• Before assigning recurring value to HALO, seek verifiable disclosure on affected European launch sales, potential royalties or damages, and expected litigation costs. No read-through to ENHANZE license revenue is warranted absent evidence that those separate agreements are implicated.